In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs

BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country